Navigation Links
InterMune To Release Third Quarter Financial Results On November 7
Date:10/31/2012

BRISBANE, Calif., Oct. 31, 2012 /PRNewswire/ -- InterMune, Inc. (NASDAQ: ITMN) today announced that it will release its third quarter and first nine months 2012 financial results at the close of the U.S. markets on Wednesday, November 7, 2012.  A live conference call and webcast will be hosted by InterMune at 4:30 p.m. Eastern time that same day.

(Logo:  http://photos.prnewswire.com/prnh/20120827/SF62570LOGO)

Interested investors and others may participate in the conference call by dialing 800-891-8257 (U.S.) or +1 212-271-4651 (international), conference ID# 21610043.  A replay of the webcast and teleconference will be available on the company's website approximately three hours after the call.  To access the live webcast, please log on to the company's website at www.intermune.com at least 15 minutes prior to the start of the call to ensure adequate time for any software downloads that may be required.

A telephonic replay will be available for 10 business days following the call and can be accessed by dialing 800-633-8284 (U.S.) or +1 402-977-9140 (international), and entering the conference ID# 21610043. 

About InterMune

InterMune is a biotechnology company focused on the research, development and commercialization of innovative therapies in pulmonology and orphan fibrotic diseases.  In pulmonology, InterMune is focused on therapies for the treatment of idiopathic pulmonary fibrosis (IPF), a progressive and fatal lung disease.  Pirfenidone, the only medicine approved  for IPF anywhere in the world, is approved for marketing by InterMune in the EU and Canada as Esbriet® and is currently in a Phase 3 clinical trial to support regulatory registration in the United States.  InterMune's research programs are focused on the discovery of targeted, small-molecule therapeutics and biomarkers to treat and monitor serious pulmonary and fibrotic diseases.  For additional information about InterMune and its R&D pipeline, please visit www.intermune.com.


'/>"/>
SOURCE InterMune, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. InterMune To Present At JMP Securities Healthcare Conference
2. InterMune to Release Fourth Quarter and Full Year Financial Results on February 9
3. InterMune to Present at J. P. Morgan Healthcare Conference
4. InterMune to Report Unaudited Fourth Quarter EsbrietĀ® Revenue and Business Update on January 5
5. New technology delivers sustained release of drugs for up to 6 months
6. ClearCanvas Releases New Workstation Products Designed to Assist With Image Sharing
7. PhoenixSongs Biologicals, Inc. Announces Enhanced Neural Lineage-specific Cell Culture Media Products Release
8. Clinical Site Services Chris Trizna Contributing Author in Diana Anderson-Fosters Newest Release Global Issues in Patient Recruitment and Retention
9. Life Technologies Sets 2nd Quarter 2012 Earnings Release Date for Tuesday, July 31, 2012
10. WuXi PharmaTech Schedules Second-Quarter 2012 Earnings Release
11. Happtique Releases Draft App Certification Program Standards For Public Comment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... ... February 10, 2016 , ... SonaCare ... training and support program, Sonalinkā„¢ remote monitoring. The inaugural launch of this new ... February 5th, connecting Dr. Samuel Peretsman to a HIFU technical expert at SonaCare ...
(Date:2/10/2016)... BC (PRWEB) , ... February 09, 2016 , ... ... design services and current winner of the Highest Overall Customer Rating Award ... in all of its business units across the USA, Canada, Mexico and China. ...
(Date:2/9/2016)... ... February 09, 2016 , ... ... innovations on its free and validated Electronic Data Capture (EDC) system ClinCaptureand its ... in Clinical Trials West Coast 2016 Conference in San Mateo, California on February ...
(Date:2/9/2016)... , Feb. 9, 2016  DNAtrix, ... immunotherapies for cancer, announced that its lead ... European Commission as an orphan medicinal product ... deadliest form of glioma, strikes approximately 25,000 ... EU. http://photos.prnewswire.com/prnh/20160208/330986LOGO ...
Breaking Biology Technology:
(Date:2/2/2016)... , Feb. 2, 2016  Based on its ... & Sullivan recognizes US-based Intelligent Retinal Imaging Systems ... Sullivan Award for New Product Innovation. IRIS, a ... North America , is poised to ... growing diabetic retinopathy market. The IRIS technology presents ...
(Date:1/28/2016)... JOSE, Calif., Jan. 28, 2016 Synaptics (NASDAQ: SYNA ... results for its second quarter ended December 31, 2015. ... second quarter of fiscal 2016 increased 2 percent compared to the ... second quarter of fiscal 2016 was $35.0 million, or $0.93 per ... Non-GAAP net income for the first quarter of fiscal 2016 grew ...
(Date:1/22/2016)... , January 22, 2016 /PRNewswire/ ... announced the addition of the  "Global ... their offering. --> http://www.researchandmarkets.com/research/4lmf2s/global_behavioral ... the  "Global Behavioral Biometric Market 2016-2020" ... Research and Markets ( http://www.researchandmarkets.com/research/4lmf2s/global_behavioral ) ...
Breaking Biology News(10 mins):